Erratum to: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens

**Chad J. Reissig · Lawrence P. Carter ·
Matthew W. Johnson · Miriam Z. Mintzer ·
Margaret A. Klinedinst · Roland R. Griffiths**

Published online: 19 June 2013
© Springer-Verlag Berlin Heidelberg 2013

Erratum to: Psychopharmacology
DOI 10.1007/s00213-012-2680-6

Unfortunately, in the original publication of this article, the dose formulation was reported incorrectly. The section on Drugs in the “Materials and Methods” section should read as follows:

Drugs

Drugs and placebo were orally administered in size 0 aqua-colored opaque capsules with approximately 200 ml of water. Four identical capsules were administered in each drug session containing lactose monohydrate (Ruger Chemical Company, Linden, NJ, USA) and appropriate quantities of powdered dextromethorphan (Spectrum Chemical, Gardena, CA, USA) or triazolam tablets (Halcion; The Upjohn Company, Kalamazoo, MI, USA). Doses of dextromethorphan are expressed as the base.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00213-012-2680-6>.

C. J. Reissig · M. W. Johnson · M. Z. Mintzer · M. A. Klinedinst ·
R. R. Griffiths (✉)
Department of Psychiatry and Behavioral Sciences, Johns Hopkins
University School of Medicine, 5510 Nathan Shock Drive,
Baltimore, MD 21224-6823, USA
e-mail: rgriff@jhmi.edu

R. R. Griffiths
Department of Neuroscience, Johns Hopkins University School of
Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224-6823,
USA

L. P. Carter
Department of Pharmacology and Toxicology, University of
Arkansas for Medical Sciences, Little Rock, AR 72205, USA